Evidence-based clinical practice guidelines for irritable bowel syndrome. (Q35513973)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Evidence-based clinical practice guidelines for irritable bowel syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Shin Fukudo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hiroshi Kaneko

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hirotada Akiho

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Masahiko Inamori

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yuka Endo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Motoyori Kanazawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Takeshi Kamiya

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ken Sato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Toshimi Chiba

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kenji Furuta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Shigeru Yamato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Tetsuo Arakawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yoshihide Fujiyama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Takeshi Azuma

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kazuma Fujimoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Tetsuya Mine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Soichiro Miura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yoshikazu Kinoshita

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kentaro Sugano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Tooru Shimosegawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

12 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

11-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25500976%20AND%20SRC:MED&resulttype=core&format=json

Functional bowel disorders

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Gastrointestinal symptoms and obesity: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Postinfectious irritable bowel syndrome--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The impact of irritable bowel syndrome on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Predictors of health care seeking for irritable bowel syndrome: a population based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on FMRI and dynamic causal modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Candidate genes and sensory functions in health and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Colonic transit time and IBS symptoms: what's the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Irritable bowel syndrome aggregates strongly in families: a family-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Colonoscopy as an adjunctive method for the diagnosis of irritable bowel syndrome: focus on pain perception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Prospective diary evaluation of unexplained abdominal pain and bowel dysfunction: a population-based colonoscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Self-management for women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Use of serum biomarkers in a diagnostic test for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The irritable bowel syndrome: long-term prognosis and the physician-patient interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Review article: probiotics and prebiotics in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

An evidence-based treatment algorithm for IBS based on a bacterial/SIBO hypothesis: Part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The role of rifaximin therapy in patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Evaluation of drug treatment in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Advances in pharmacological treatments of IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Irritable bowel syndrome: current approach to symptoms, evaluation, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Constipation: evaluation and treatment of colonic and anorectal motility disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Diagnosis and management of IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of the acute use of sodium picosulphate in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The placebo effect in irritable bowel syndrome trials: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Defining the predictors of the placebo response in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Long term benefits of hypnotherapy for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Hypnotherapy for functional gastrointestinal disorders: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Integrative medicine in gastrointestinal disease: evaluating the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Systematic review: Complementary and alternative medicine in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Herbal medicines for treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

A randomized trial of yoga for adolescents with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Somatic comorbidities of irritable bowel syndrome: a systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Studying the overlap between IBS and GERD: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Ulcerative colitis and irritable bowel syndrome: relationships with quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Tolerability and effect of mesalazine in postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1017-0

Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis

21 January 2018

1 reference

12 December 2020

Loperamide treatment of the irritable bowel syndrome

1 reference

12 December 2020

Hypnotherapy for treatment of irritable bowel syndrome

1 reference

12 December 2020

Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study

1 reference

12 December 2020

Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome

1 reference

12 December 2020

A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin

1 reference

12 December 2020

Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study

1 reference

12 December 2020

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

1 reference

12 December 2020

Acupuncture for treatment of irritable bowel syndrome

1 reference

12 December 2020

Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients

1 reference

12 December 2020

Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome.

1 reference

12 December 2020

Psychological treatments for the management of irritable bowel syndrome

1 reference

12 December 2020

Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome

1 reference

12 December 2020

Different therapeutic regimens in irritable bowel syndrome

1 reference

12 December 2020

Possible role of nitric oxide in visceral hypersensitivity in patients with irritable bowel syndrome

1 reference

12 December 2020

Differential responding of autonomic function to histamine H1 antagonism in irritable bowel syndrome

1 reference

12 December 2020

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

1 reference

12 December 2020

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review

1 reference

12 December 2020

A controlled trial of psychological treatment for the irritable bowel syndrome

1 reference

12 December 2020

Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

1 reference

12 December 2020

Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome

1 reference

12 December 2020

Calcium polycarbophil compared with placebo in irritable bowel syndrome.

1 reference

12 December 2020

Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology

1 reference

12 December 2020

Serotonin 5- HT4 receptor agonist (mosapride citrate)

1 reference

12 December 2020

Effects of desipramine on irritable bowel syndrome compared with atropine and placebo

1 reference

12 December 2020

Symptomatic overlap between irritable bowel syndrome and microscopic colitis

1 reference

12 December 2020

Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial

1 reference

12 December 2020